Clinical Trials Logo

Intestinal Diseases clinical trials

View clinical trials related to Intestinal Diseases.

Filter by:

NCT ID: NCT03509220 Completed - Clinical trials for Gastrointestinal Disease

Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy

Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy, safety and tolerability of PBK-1701TC for bowel cleansing before colonoscopy. Half the participants will receive PBK-1701TC and while the other will receive standard oral preparation.

NCT ID: NCT03500653 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

Start date: June 9, 2020
Phase: N/A
Study type: Interventional

Introduction: The pathogenesis of inflammatory bowel diseases (IBD) is characterized by dysregulation of the innate immune response it's associated with Th1, Th17 up-regulation, reflected by increased cytokine secretion including TNF-α. A main effective therapeutic interventions is blocking TNFα. Vedolizumab, an anti integrin, is a new class of treatment designed to block trafficking of lymphocytes in the gut. Clinical trials and real life experience response rates at week 6 range between 30-45%. Curcumin suppresses NFκβ levels via alteration of TLR2/4 pathways lowering TNF-α upstream. Curcumin is safe and efficacious in inducing response and remission in mild-moderate Ulcerative colitis (UC) and maintaining remission when used as an add-on to 5ASA derivatives, only with strict adherence to treatment overtime. Objectives: Facing the low rate of response to therapies in IBD, the need for new treatments and the use of combination strategies lead us to believe that combining vedolizumab and curcumin may have a synergistic effect and will enable optimal immunomodulation. Hypothesis: Concomitant oral curcumin in IBD patients with colonic involvement will augment remission rates as well as clinical and biochemical response. Type of research and methods of data collection: A randomized controlled trial in 84 adults with colonic IBD (UC and CD). Eligible patients are during vedolizumab induction, patients will randomized will be into curcumin or placebo. Data will managed by investigators.

NCT ID: NCT03496246 Enrolling by invitation - Clinical trials for Inflammatory Bowel Diseases

Vitamin D Status in Inflammatory Bowel Disease

vdsinibd
Start date: April 2018
Phase: N/A
Study type: Interventional

Inflammatory bowel disease (IBD), comprising crohn's disease (CD) and ulcerative colitis (UC), is a a chronic, relapsing-remitting systemic disease. Vitamin D is a secosteroid hormone that possesses immunomodulatory properties and has been demonstrated to potentially influence inflammatory bowel disease (IBD) pathogenesis and activity.

NCT ID: NCT03490435 Completed - Chronic Disease Clinical Trials

Intestinal Parasites in Inhabitants of Kuyavian-Pomeranian Province in Poland

Start date: February 17, 2018
Phase:
Study type: Observational

The goal of the proposed study is to assess the prevalence of intestinal parasitic diseases in adults and children. These invasions are included to "dirty hand diseases" (per os invasions), therefore it applies mainly preschool children.

NCT ID: NCT03488030 Completed - Crohn Disease Clinical Trials

A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)

RISE AR
Start date: December 12, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the percentage of moderate to severe IBD participants with active disease at Day 1.

NCT ID: NCT03487926 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

Microglial Activation in Inflammatory Bowel Disease

Start date: September 14, 2022
Phase:
Study type: Observational

The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD and MDE will be subsequently approached to participate in the study.

NCT ID: NCT03486652 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Rheumatological Manifestations in Inflammatory Bowel Diseases

Start date: May 1, 2018
Phase:
Study type: Observational

IBD-related arthropathy is one of a group of inflammatory arthritides considered as seronegative spondyloarthropathies, a group of disorders that also includes ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and undifferentiated SpA. IBD-related SpA is mainly characterized by axial involvement but may also be associated with peripheral symptoms, such as synovitis, dactylitis, or enthesitis

NCT ID: NCT03486158 Completed - Clinical trials for Inflammatory Bowel Diseases

The CalproSmartNOR Study - a New Clinical Tool for Monitoring Patients With Inflammatory Bowel Disease

Start date: March 15, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to prove that getting immediate calprotectin test results on the patients Smartphone (platforms such as Android or Iphone), will both stimulate patients with inflammatory bowel disease (IBD) to closer follow up of their disease, and that immediate automatic e-mails to a IBD-nurse will lead to earlier decision-making on further treatment and follow-up by health personnel (optimized medication, endoscopy etc).

NCT ID: NCT03477032 Recruiting - Ulcerative Colitis Clinical Trials

FMT in Inflammatory Bowel Disease

Start date: June 1, 2018
Phase:
Study type: Observational

This is a prospective observational cohort study, over 52 weeks, evaluating the the use of faecal microbiota transplantation amongst patients with Inflammatory Bowel Disease and Microscopic Colitis

NCT ID: NCT03463304 Completed - Clinical trials for Mental Health Wellness 1

Environmental Factors and the Gut Microbiome - Endocannabinoid Axis

eMECA
Start date: February 13, 2018
Phase:
Study type: Observational

The general objective of this project is to investigate the interplay of the gut microbiome - endocannabinoid axis with host environmental factors and intestinal, metabolic and mental health status in free-living adults with various metabolic statuses and lifestyles.